Teva Pharma CEO: Guidance based on the new Teva that grows every year
Richard Francis, Teva Pharmaceuticals CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, drug price negotiations, and much more.
Teva Pharmaceutical Industries Limited (TEVA) Q4 2024 Earnings Conference Call Transcript
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q4 2024 Earnings Conference Call January 29, 2025 8:00 AM ET Company Participants Christopher Stevo - SVP, IR Richard Francis - President & CEO Eric Hughes - Head of R&D & Chief Medical Officer Eli Kalif - CFO Conference Call Participants Umer Raffat - Evercore ISI Jason Gerberry - Bank of America David Amsellem - Piper Sandler Balaji Prasad - Barclays Ash Verma - UBS Yifeng Liu - HSBC Glen Santangelo - Jefferies Chris Schulz - J.P. Morgan Operator Hello, and welcome to the Fourth Quarter and Full-Year 2024 Teva Pharmaceutical Industries Earnings Conference Call.
Teva Pharmaceutical Industries (TEVA) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Teva Pharm Q4 tops estimates on strong sales of its own drugs
Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit sales gains in a trio of its branded drugs to treat migraines, Huntington's disease and schizophrenia.
Pharmaceutical Name Gearing Up for Earnings
Israel-based pharmaceutical giant Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is preparing for its latest quarterly earnings report, due out before the open Wednesday, Jan. 29.
Teva Pharmaceutical Industries Limited (TEVA) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 11:15 AM ET Company Participants Richard Francis - President and CEO Eric Hughes - Head of R&D and Chief Medical Officer Conference Call Participants Chris Schott - J.P.
Teva Pharmaceuticals CEO talks Trump and US healthcare
Pharmaceutical companies brace for the upcoming Trump administration. Teva Pharmaceuticals (TEVA) CEO Richard Francis joins Seana Smith and Madison Mills on Catalysts to discuss what both the pharmaceutical company and industry at large are expecting from Trump's return to the White House.
Teva CEO on Drug Pricing, Generics, Supply Shortages
Teva Pharmaceuticals CEO Richard Francis reflects on company performance in 2024, drug pricing, getting more drugs to market, supply shortages of the drug Adderall, and selling GLP-1 drugs. He speaks to "Bloomberg Open Interest" from the JPMorgan Healthcare Conference.
Duvakitug And Teva's Growth: A Game Changer In Pharma
On December 17, Teva Pharmaceutical Industries Limited reported that duvakitug had shown stunning results in a phase 2b study for the treatment of Crohn's disease and ulcerative colitis. However, a month and a half before this news, the Israeli pharmaceutical company pleased investors by once again beating analysts' expectations by a wide margin. So, Uzedy's sales amounted to $35 million in the third quarter of 2024, increasing more than 16 times year-on-year.
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Teva Pharmaceutical Industries Ltd. TEVA and Sanofi SA's SNY Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn's disease (CD).
Strength Seen in Teva Pharmaceutical Industries (TEVA): Can Its 26.5% Jump Turn into More Strength?
Teva Pharmaceutical Industries (TEVA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
TEVA stock soars 26%: What's going on with Teva Pharmaceuticals?
Teva Pharmaceuticals (NASDAQ: TEVA) and its partner Sanofi (NASDAQ: SNY) have announced groundbreaking results from clinical trials of their drug, duvakitug, for ulcerative colitis and Crohn's disease, two of the most prevalent forms of inflammatory bowel disease (IBD). The announcement, which sent Teva's stock soaring by 26.4% to $20.88 and Sanofi's up 6.7% to $48.
